These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35294390)

  • 41. The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women.
    Orr-Walker BJ; Evans MC; Ames RW; Clearwater JM; Cundy T; Reid IR
    Clin Endocrinol (Oxf); 1998 Nov; 49(5):615-8. PubMed ID: 10197077
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Observational study of the acceptability of Sayana® Press among intramuscular DMPA users in Uganda and Senegal.
    Burke HM; Mueller MP; Perry B; Packer C; Bufumbo L; Mbengue D; Mall I; Daff BM; Mbonye AK
    Contraception; 2014 May; 89(5):361-7. PubMed ID: 24631328
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost-effectiveness of self-injected DMPA-SC compared with health-worker-injected DMPA-IM in Senegal.
    Mvundura M; Di Giorgio L; Morozoff C; Cover J; Ndour M; Drake JK
    Contracept X; 2019; 1():100012. PubMed ID: 32494776
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Serum immunoglobulin levels during contraceptive use of depot-medroxyprogesterone acetate in Indian women: a preliminary study.
    Lali P; Chandra L; Gupta RP
    Contraception; 1996 Jun; 53(6):363-5. PubMed ID: 8773424
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Contraceptive self-injection through routine service delivery: Experiences of Ugandan women in the public health system.
    Cover J; Namagembe A; Morozoff C; Tumusiime J; Nsangi D; Drake JK
    Front Glob Womens Health; 2022; 3():911107. PubMed ID: 36060608
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ugandan providers' views on the acceptability of contraceptive self-injection for adolescents: a qualitative study.
    Cover J; Namagembe A; Tumusiime J; Lim J; Cox CM
    Reprod Health; 2018 Oct; 15(1):165. PubMed ID: 30285779
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Self-care provision of contraception: Evidence and insights from contraceptive injectable self-administration.
    Brady M; Drake JK; Namagembe A; Cover J
    Best Pract Res Clin Obstet Gynaecol; 2020 Jul; 66():95-106. PubMed ID: 32199705
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effectiveness of Cyclofem in the treatment of depot medroxyprogesterone acetate induced amenorrhea.
    Piya-Anant M; Koetsawang S; Patrasupapong N; Dinchuen P; d'Arcangues C; Piaggio G; Pinol A
    Contraception; 1998 Jan; 57(1):23-8. PubMed ID: 9554247
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Perspectives on DMPA-SC for self-injection among adolescents with unmet need for contraception in Malawi.
    Ali G; Porter Erlank C; Birhanu F; Stanley M; Chirwa J; Kachale F; Gunda A
    Front Glob Womens Health; 2023; 4():1059408. PubMed ID: 37034400
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bone density in long term users of depot medroxyprogesterone acetate.
    Gbolade B; Ellis S; Murby B; Randall S; Kirkman R
    Br J Obstet Gynaecol; 1998 Jul; 105(7):790-4. PubMed ID: 9692421
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Self-administration of injectable contraception: a systematic review and meta-analysis.
    Kennedy CE; Yeh PT; Gaffield ML; Brady M; Narasimhan M
    BMJ Glob Health; 2019; 4(2):e001350. PubMed ID: 31179026
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacist-administered subcutaneous depot medroxyprogesterone acetate: a pilot randomized controlled trial.
    Picardo C; Ferreri S
    Contraception; 2010 Aug; 82(2):160-7. PubMed ID: 20654757
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Characteristics of injectable contraceptive users in a low-income population in Texas.
    Sangi-Haghpeykar H; Poindexter AN; Moseley DC; Bateman L; Reid ED
    Fam Plann Perspect; 1995; 27(5):208-11, 225. PubMed ID: 9104608
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Self-administered subcutaneous medroxyprogesterone acetate for improving contraceptive outcomes: a systematic review and meta-analysis.
    Nabhan A; Elshafeey F; Mehrain LM; Kabra R; Elshabrawy A
    BMC Womens Health; 2021 Oct; 21(1):359. PubMed ID: 34627229
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Scale-up of the DMPA-SC in Nigeria: Why policy matters.
    Akinyemi O; Danfakha N; Adefalu A; Easley E; Afolabi K; Latunji O
    BMC Womens Health; 2022 Dec; 22(1):535. PubMed ID: 36544189
    [TBL] [Abstract][Full Text] [Related]  

  • 56. WHO special programme of research, development and research training in human reproduction. Task force on long-acting agents for the regulation of fertility.
    Contraception; 1982 Jan; 25(1):1-11. PubMed ID: 6460593
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Self-administration of subcutaneous depot medroxyprogesterone acetate for contraception: feasibility and acceptability.
    Prabhakaran S; Sweet A
    Contraception; 2012 May; 85(5):453-7. PubMed ID: 22079605
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A randomized, single blind comparative trial of norethindrone enanthate and depo-medroxyprogesterone acetate in Bangladesh.
    Swenson I; Khan AR; Jahan FA
    Contraception; 1980 Mar; 21(3):207-15. PubMed ID: 6446442
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Changes in weight with depot medroxyprogesterone acetate subcutaneous injection 104 mg/0.65 mL.
    Westhoff C; Jain JK; Milsom I; Ray A
    Contraception; 2007 Apr; 75(4):261-7. PubMed ID: 17362703
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Trabecular bone in long-term depot-medroxyprogesterone acetate users.
    Virutamasen P; Wangsuphachart S; Reinprayoon D; Kriengsinyot R; Leepipatpaiboon S; Gua C
    Asia Oceania J Obstet Gynaecol; 1994 Sep; 20(3):269-74. PubMed ID: 7811192
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.